| Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. | |
| | |
MedLine Citation:
|
PMID: 22337679 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: Vitamin D is associated with decreased cardiovascular-related morbidity and mortality, possibly by modifying cardiac structure and function, yet firm evidence for either remains lacking. OBJECTIVE: To determine the effects of an active vitamin D compound, paricalcitol, on left ventricular mass over 48 weeks in patients with an estimated glomerular filtration rate of 15 to 60 mL/min/1.73 m(2). DESIGN, SETTING, AND PARTICIPANTS: Multinational, double-blind, randomized placebo-controlled trial among 227 patients with chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved left ventricular ejection fraction, conducted in 11 countries from July 2008 through September 2010. INTERVENTION: Participants were randomly assigned to receive oral paricalcitol, 2 μg/d (n =115), or matching placebo (n = 112). MAIN OUTCOME MEASURES: Change in left ventricular mass index over 48 weeks by cardiovascular magnetic resonance imaging. Secondary end points included echocardiographic changes in left ventricular diastolic function. RESULTS: Treatment with paricalcitol reduced parathyroid hormone levels within 4 weeks and maintained levels within the normal range throughout the study duration. At 48 weeks, the change in left ventricular mass index did not differ between treatment groups (paricalcitol group, 0.34 g/m(2.7) [95% CI, -0.14 to 0.83 g/m(2.7)] vs placebo group, -0.07 g/m(2.7) [95% CI, -0.55 to 0.42 g/m(2.7)]). Doppler measures of diastolic function including peak early diastolic lateral mitral annular tissue velocity (paricalcitol group, -0.01 cm/s [95% CI, -0.63 to 0.60 cm/s] vs placebo group, -0.30 cm/s [95% CI, -0.93 to 0.34 cm/s]) also did not differ. Episodes of hypercalcemia were more frequent in the paricalcitol group compared with the placebo group. CONCLUSION: Forty-eight week therapy with paricalcitol did not alter left ventricular mass index or improve certain measures of diastolic dysfunction in patients with chronic kidney disease. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00497146. |
| | |
Authors:
|
Ravi Thadhani; Evan Appelbaum; Yili Pritchett; Yuchiao Chang; Julia Wenger; Hector Tamez; Ishir Bhan; Rajiv Agarwal; Carmine Zoccali; Christoph Wanner; Donald Lloyd-Jones; Jorge Cannata; B Taylor Thompson; Dennis Andress; Wuyan Zhang; David Packham; Bhupinder Singh; Daniel Zehnder; Amil Shah; Ajay Pachika; Warren J Manning; Scott D Solomon |
Related Documents
:
|
11331259 - Bidirectional glenn procedure improves the mechanical efficiency of a total cavopulmona... 20113219 - Computed tomographic evaluation of cerebral ventricular size in clinically normal calves. 3752639 - Development and use of a remote-controlled mitral valve. 19108909 - Real three-dimensional assessment of left atrial and left atrial appendage volumes by 6... 6884099 - Effect of timolol on exercise-induced reduction in regional ejection fraction in patien... 9554649 - Reproducibility of double indicator dilution measurements of intrathoracic blood volume... 3015489 - Adrenergic regulation of the acute ischaemic myocardium: facts, interpretations and con... 17264959 - Fibrinogen gene haplotypes in relation to risk of coronary events and coronary and extr... 8968669 - Transmyocardial laser revascularization. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: JAMA : the journal of the American Medical Association Volume: 307 ISSN: 1538-3598 ISO Abbreviation: JAMA Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-02-16 Completed Date: 2012-02-16 Revised Date: 2012-06-19 |
Medline Journal Info:
|
Nlm Unique ID: 7501160 Medline TA: JAMA Country: United States |
Other Details:
|
Languages: eng Pagination: 674-84 Citation Subset: AIM; IM |
Affiliation:
|
Division of Nephrology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA. thadhani.r@mgh.harvard.edu |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00497146 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Chronic Disease Double-Blind Method Ergocalciferols / pharmacology, therapeutic use* Female Glomerular Filtration Rate Humans Hypercalcemia / chemically induced Hyperparathyroidism, Secondary / drug therapy Hypertrophy, Left Ventricular / drug therapy*, etiology Kidney Diseases / complications* Male Middle Aged Parathyroid Hormone / blood Treatment Outcome Ventricular Function, Left / drug effects* Vitamin D Deficiency / complications, drug therapy*, etiology Vitamins / pharmacology, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Ergocalciferols; 0/Parathyroid Hormone; 0/Vitamins; 131918-61-1/paricalcitol |
| Comments/Corrections | |
Comment In:
|
JAMA. 2012 Jun 6;307(21):2253; author reply 2254
[PMID:
22706819
]
JAMA. 2012 Jun 6;307(21):2253; author reply 2254 [PMID: 22706820 ] JAMA. 2012 Feb 15;307(7):722-3 [PMID: 22337683 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Altering surface characteristics of polypropylene mesh via sodium hydroxide treatment.
Next Document: Amoxicillin for acute rhinosinusitis: a randomized controlled trial.